Anti‐tumor necrosis factor‐α monotherapy versus combo therapy with immunosuppressant in pediatric inflammatory bowel disease: A real‐life study
Journal of Pediatric Gastroenterology and Nutrition · 2026
DOI: 10.1002/jpn3.70280 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2026. Verfasst von Flora Fedele und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II", Naples, Italy. Hauptthemen laut MEDLINE: Immunosuppressive Agents, Tumor Necrosis Factor-alpha, Colitis, Ulcerative, Crohn Disease. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: None.
Abstract (Originalsprache)
Objectives
The aim of the study is to evaluate the efficacy of anti‐tumor necrosis factor (TNF)‐α monotherapy versus combination anti‐TNF‐α and immunosuppressive therapy.
Methods
A single‐center, retrospective, observational study was conducted on inflammatory bowel disease (IBD) children. Patients with at least 6 months of follow‐up were enrolled and divided into two groups based on therapy. Combo group included children on combination anti‐TNF‐α and immunosuppressant therapy; children undergoing anti‐TNF‐α monotherapy were assigned to Mono group.
Results
One hundred and seventeen children were enrolled, of whom 74 (63.2%) were affected by Crohn's disease (CD) and 43 (36.8%) by ulcerative Colitis (UC) (median age at diagnosis: 11.6 years; range 2.1–16.9; M/F: 56/61). Eighty patients (68.4%) were included in combo group and 37 (31.6%) in mono group. The median follow‐up was 2.6 years (0.5–11.3). Twenty‐three patients out of 80 (28.7%) in Group 1 showed therapy failure compared with 21/37 (56.8%) children in Mono group ( p = 0.04). CD patients in monotherapy showed a significantly increased risk of therapy failure than those treated with combination therapy ( p < 0.001). Conversely, no difference was found in UC children ( p = 0.7). Children undergoing a reactive approach showed more frequent therapy failure compared to proactive in both groups (combo group: 41.7% vs. 4.3%; p = 0.01; mono group: 87.5% vs. 20%; p = 0.01). In a multivariate regression model, the use of a proactive approach and combination therapy was independently associated with anti‐TNF‐α durability (odds ratio [OR] = 22.1, OR = 12.9).
Conclusion
Combination therapy reduced overall anti‐TNF‐α failure in CD children, but not in UC patients. Additionally, a proactive approach was associated with increased anti‐TNF‐α durability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II", Naples, Italy.
- Department of Woman, Child and General and Specialistic Surgery, University of Campania "Luigi Vanvitelli", Napoli, Italy.
ORCID-Profile: Massimo Martinelli
Förderung
- None
Zitieren
APA
Fedele, F., Martinelli, M., Strisciuglio, C., Scarpato, E., Staiano, A., & Miele, E. (2026). Anti‐tumor necrosis factor‐α monotherapy versus combo therapy with immunosuppressant in pediatric inflammatory bowel disease: A real‐life study. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70280
Vancouver
Fedele F, Martinelli M, Strisciuglio C, Scarpato E, Staiano A, Miele E. Anti‐tumor necrosis factor‐α monotherapy versus combo therapy with immunosuppressant in pediatric inflammatory bowel disease: A real‐life study. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70280
BibTeX
@article{Fedele2026,
author = {Fedele, Flora and Martinelli, Massimo and Strisciuglio, Caterina and Scarpato, Elena and Staiano, Annamaria and Miele, Erasmo},
title = {Anti‐tumor necrosis factor‐α monotherapy versus combo therapy with immunosuppressant in pediatric inflammatory bowel disease: A real‐life study},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70280}
}
EUVIMED